Monocyte

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Retrieved on: 
Tuesday, February 27, 2024

DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces publication of a manuscript discussing the role of chronic dysregulated systemic inflammation in heart failure and the potential application of the adult Selective Cytopheretic Device, part of the Quelimmune™ product family, in enabling previously ineligible patients with severe disease to receive a left ventricular assist device (LVAD) or heart transplant in the peer-reviewed European Journal of Heart Failure February 2024, Pitt, B., Iyer, S.P.N. and Humes, H.D. (2024), Eur J Heart Fail. https://doi.org/10.1002/ejhf.3177.

Key Points: 
  • The manuscript, titled “New Opportunity for Targeting Systemic Inflammation in Patients with Heart Failure through Leukocyte Immunomodulation” cites increasing evidence of the role of chronic systemic inflammation in patients with heart failure and discusses the Adult SCD’s potential to improve hypertensive heart failure and mortality following hospitalization for acute or worsening heart failure.
  • Following treatment with the Adult SCD, this patient was effectively bridged to LVAD three days after discontinuing treatment and was subsequently discharged without further complications.
  • “Prior attempts targeting singular proinflammatory factors as well as systemic immunosuppression with glucocorticoids in patients with acute heart failure have yielded unclear results, raising the need to identify new strategies.
  • “While our manuscript discusses a positive outcome in one patient following treatment for six hours daily over six consecutive days, the results suggest that more study with Adult SCD is warranted for patients with heart failure and hyperinflammation.”

Immunis.AI Announces Publication, in The Journal of Urology, of Results from Blood-Based Immune Profiling Study for Prostate Cancer Patients

Retrieved on: 
Friday, March 1, 2024

The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.

Key Points: 
  • The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.
  • “One of the big challenges in prostate cancer management is distinguishing those patients with early prostate cancer who are appropriate for active surveillance from those who need to be aggressively treated.
  • In the study, peripheral blood samples were collected from 706 subjects with confirmed prostate cancer based on positive biopsy.
  • Using AI predictive modeling, the normalized immune profile of each patient was evaluated against known immune signatures for indolent or aggressive prostate cancer.

Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product

Retrieved on: 
Thursday, February 29, 2024

Depletion of either of these cells significantly reduced therapeutic effects of JadiCells.

Key Points: 
  • Depletion of either of these cells significantly reduced therapeutic effects of JadiCells.
  • Additionally, transfer of monocytes and T cells from JadiCell treated mice was able to protect naïve mice from lung injury.
  • The therapeutic effect of JadiCells was amplified by administration of Leukine (GM-CSF), which is known to increase circulating monocytes.
  • We are dedicated to curing this terrible disease1 and making our cells the new standard of care.”

Pusan National University Researchers Reveal How Diabetes Weakens Gum Defense

Retrieved on: 
Friday, February 16, 2024

BUSAN, South Korea, Feb. 16, 2024 /PRNewswire/ -- Periodontitis (PD) is a common complication in individuals with diabetes mellitus (DM). Despite the profound implications for overall health, the complex bidirectional relationship between them lacks a comprehensive understanding so far, leaving the precise nature of their immunological connection inadequately understood. Prior studies focusing on local immune responses in gingival tissue fall short in capturing the systemic immunological relationship.

Key Points: 
  • BUSAN, South Korea, Feb. 16, 2024 /PRNewswire/ -- Periodontitis (PD) is a common complication in individuals with diabetes mellitus (DM).
  • In an innovative study, researchers from the Republic of Korea have investigated the relationship between periodontitis (PD) and diabetes mellitus (DM).
  • Led by Assistant Professor Yun Hak Kim from Pusan National University, the study employs pioneering single-cell RNA analysis and digs into the immune dynamics at the cellular level.
  • In conclusion, this groundbreaking research provides a first-of-its-kind immunological explanation for the complex association between periodontitis and type 2 diabetes mellitus.

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Retrieved on: 
Tuesday, January 30, 2024

TEL AVIV, Israel, Jan. 30, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced publication of proteomic analyses that further demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The new studies reinforce the extensive existing evidence showing that Chemomab's first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes. The study, "The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data"1 has been published in the current online version of the peer-reviewed journal Cells.

Key Points: 
  • The new studies reinforce the extensive existing evidence showing that Chemomab's first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes.
  • The study, " The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data "1 has been published in the current online version of the peer-reviewed journal Cells.
  • CM-101 is a first-in-class CCL24-neutralizing monoclonal antibody whose dual anti-inflammatory and anti-fibrotic activity has demonstrated disease modifying potential in nonclinical studies of PSC and other fibro-inflammatory disorders.
  • CM-101 has Orphan Drug designation for PSC in the U.S. and the European Union and was recently awarded Fast Track designation by the FDA for the treatment of PSC in adults.

SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications

Retrieved on: 
Tuesday, January 9, 2024

11,866,730 with broad claims directed to methods of using the Selective Cytopheretic Device (SCD) to treat subjects with inflammatory conditions and to process activated leukocytes and platelets.

Key Points: 
  • 11,866,730 with broad claims directed to methods of using the Selective Cytopheretic Device (SCD) to treat subjects with inflammatory conditions and to process activated leukocytes and platelets.
  • The SCD is a first-in-class, cell-directed extracorporeal therapy that selectively targets highly active inflammatory cells to quell the inflammatory response.
  • “This patent significantly fortifies our intellectual property portfolio and is highly supportive of our strategy to validate our technology’s application across multiple high-value clinical indications in which hyperinflammation plays a role,” said Eric Schlorff, CEO of SeaStar Medical.
  • Our SCD therapy works to selectively target the most highly activated cells responsible for inflammation to bring activated cells into a reparative state.

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Retrieved on: 
Monday, January 8, 2024

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced initial data for its PRC2 inhibitor ORIC-944, operational highlights for 2023, and anticipated upcoming milestones.

Key Points: 
  • Presented initial data from the ongoing Phase 1b dose escalation trial for patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer (NSCLC) at the ESMO Congress 2023.
  • Presented preclinical data for ORIC-114 at ESMO Congress 2023, demonstrating potent activity across atypical mutations in EGFR, thus expanding the potential patient population.
  • Presented preclinical data highlighting a comprehensive biomarker strategy for the ongoing Phase 1b trial in metastatic prostate cancer at the 2023 AACR Annual Meeting.
  • Presented initial data from Phase 1b trial of ORIC-533 in patients with relapsed/refractory multiple myeloma at the 2023 ASH Annual Meeting.

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised